- The newly approved treatment provides a fast-acting option for acute ischemic stroke (AIS) care.
- Administered as a single IV bolus over a period of five to ten seconds, the treatment offers a significant improvement over regular one-hour-long treatments.
Dubai, United Arab Emirates – 27 February 2025: Boehringer Ingelheim, a leading research-driven biopharmaceutical company, has launched a new acute ischemic stroke (AIS) medication with active ingredient Tenecteplase 25mg to enhance emergency stroke treatment in the UAE, offering a faster and more effective treatment option for emergency stroke care.
Continue reading Boehringer Ingelheim Launches Fast-acting Stroke Medication in the UAE, Reducing Treatment Administration to Five Seconds




